Percentages of patients with (A) minimal important difference ≥0.22 on the Health Assessment Questionnaire Disability Index (HAQ DI) and (B) normal function defined as HAQ DI ≤0.5 over long-term adalimumab (ADA) treatment. Observed data are reported. LO, last observation.
Burmester et al. Arthritis Research & Therapy 2014 16:R24 doi:10.1186/ar4452